Skip to main content
66°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
788.50
-2.74 (-0.35%)
Streaming Delayed Price
Updated: 10:55 AM EDT, Jun 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Today 10:47 EDT
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.
Via
Benzinga
Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake
Today 10:41 EDT
Healthcare stocks are lagging the market by the widest margin since 2008. Analysts and valuation trends point to a rebound.
Via
Benzinga
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Today 9:53 EDT
Via
The Motley Fool
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Today 7:45 EDT
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is the Market Bullish or Bearish on Eli Lilly?
June 16, 2025
Via
Benzinga
Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)
Today 4:20 EDT
Hims & Hers Health shares rocketed higher over the last year, rewarding investors.
Via
The Motley Fool
Topics
Government
World Trade
Exposures
Political
Tariff
Market Monitor News June 18 (Jabil, Reddit & Verve Therapeutics UP - Solar Stocks First Solar, Sunrun & SolarEdge DOWN)
Today 2:49 EDT
Wall Street stays cool despite geopolitical tension, weak retail data, and a meltdown in solar stocks.
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 17, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Why Verve Therapeutics Stock Is Skyrocketing Today
June 17, 2025
Via
The Motley Fool
Surgery Partners Stock Slumps 13% After Company Rejects Bain Capital’s Take-Private Proposal
June 17, 2025
Chairman of the Independent Committee, Brent Turner, said the best path forward for Surgery Partners is to continue operating as an independent publicly traded company.
Via
Stocktwits
Members of Congress Are Pouring Millions Into These 7 Surprising Stocks
June 17, 2025
Via
The Motley Fool
Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’
June 17, 2025
Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share,...
Via
Stocktwits
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
June 17, 2025
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.
Via
Investor's Business Daily
Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition
June 17, 2025
Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions.
Via
Benzinga
May 2025 Industrial Manufacturing Near March 2025 Levels with 146 New Planned Capital Projects Heading into Summer
June 17, 2025
JACKSONVILLE, Fla., June 17, 2025 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads announced today the May 2025 results for its new planned capital project spending report for the Industrial...
Via
Send2Press
Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks
June 16, 2025
The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies.
Via
Stocktwits
Why Novo Nordisk Stock Sank by Nearly 4% Today
June 16, 2025
Via
The Motley Fool
These 2 Growth Stocks Are No-Brainer Buys Right Now
June 16, 2025
Via
The Motley Fool
Could Meta and Eli Lilly Trigger the Next Stock Split Boom?
June 16, 2025
Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices.
Via
MarketBeat
Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499
June 16, 2025
Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access without insurance barriers.
Via
Benzinga
Eli Lilly To Offer Highest Doses Of Weight-Loss Medicine On Its Digital Health Platform, But Retail Wants More Good News
June 16, 2025
Healthcare providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will start in early August.
Via
Stocktwits
Topics
Stocks
Exposures
US Equities
Bila Solar’s Indiana Factory Commences Production of Domestic Solar Panels, Strengthening U.S. Clean Energy Manufacturing at Key Policy Moment
June 16, 2025
Behind-the-scenes video captures this milestone for American solar — creating local jobs and reinforcing why federal support for clean energy matters
Via
News Direct
Topics
Economy
Exposures
Economy
Supply Chain
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks?
June 16, 2025
Via
The Motley Fool
Topics
Government
Exposures
Political
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
June 16, 2025
Via
The Motley Fool
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
June 15, 2025
Via
The Motley Fool
Benzinga Bulls And Bears: Eli Lilly, Okto, McDonalds — And Israel-Iran Conflict Sparks Oil Surge
June 14, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
1 Growth Stock Down 9% to Buy Right Now
June 14, 2025
Via
The Motley Fool
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased
June 13, 2025
Jefferies thinks big pharma companies are "still on the hunt" for deals.
Via
Stocktwits
Exposures
Product Safety
$1000 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today
June 13, 2025
Via
Benzinga
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
June 13, 2025
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.